🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Real-world efficacy of zanidatamab in patients with HER2 positive advanced biliary tract cancers 20 pts All pts ORR➡️40%, DCR➡️65% PFS➡️6.7 mo HER2 3+ vs 2+/ISH+ PFS➡️8.0 vs 1.4 mo ejcancer.com/article/S0959-…

🚨 Just released by National Cancer Institute Annual Report to the Nation 2025: Overall Cancer Statistics Most cancers in both men and women showed decreases in mortality. The incidence rates for certain cancers including #PancreaticCancer (and bile duct cancers in women) saw increases. Details:

CAR-T therapy in solid tumors dlvr.it/TKHWmC

Giving a talk at national meeting on MSI High GI cancers this weekend . So made these slides. Gives incidence of MSI high in all GI sites and data of all trials In MSI -H in all Gi cancers . Give me your inputs on this. May be useful for all for quick reference 🙂 OncoAlert

📢Hepatopancreaticobiliary-NET oral abstracts #ASCO25 ASCO ✅HCC 1⃣2503-A therapeutic vaccine for fibrolamellar hepatocellular carcinoma ✅Pancreatic 1⃣LBA4004-Results of a randomized phase III trial of pre-operative chemotherapy with mFOLFIRINOX or PAXG regimen for stage

📍España tarda de media 721 días en aprobar fármacos oncológicos tras el okey de la EU Medicines Agency⏱ ¿Cuántas vidas cuestan estos retrasos? Pedimos acceso a la innovación oncológica➕ágil y equitativo Accede a la info. completa elaborada por ASEICA: aseica.es/aseica-propone…

Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer European J Cancer doi.org/10.1016/j.ejca… 👉Majority are MSI CRC, few CCA & PDAC pts 👉ORR 27%, mPFS 6 mo, mOS 13 mo 🧐rare alteration, but supportive efficacy ESMO - Eur. Oncology ILCA EASL Education

Adjuvant chemotherapy compared to observation in resected biliary tract cancers: Survival meta-analysis of phase-III controlled trials European J Cancer doi.org/10.1016/j.ejca… 👉4 trials: BILCAP, ASCOT, BCAT, PRODIGE-12 👉only ASCOT met 1° EP 🧐Not convincing, we need to do

💉TFOX (=mFLOT) vs FOLFOX in 1L treatment of HER2(-) advanced gastric/GEJ adenoca PRODIGE 51- FFCD-GASTFOX The Lancet Oncology ✅ORR: 62.3% vs 53.4% ✅mPFS: 7.5 vs 6.6 mo, p=0.007 ✅mOS: 15 vs 12.6 mo, p=0.048 🚨G3-4 AE: diarrhoea 15% vs 7%, neuropathy 32% vs 20%, neutropenia 27%

Treatment Algorithm: This is the algorithm to reference during our discussion w/ Ghassan Abou-Alfa on Biliary Tract Cancers! #OncTwitter #MedTwitter #gism PER

#AACR25 VS-7375 (GFH375): An oral, selective KRAS G12D (ON/OFF) inhibitor with potent anti-tumor efficacy as single agent and in combination with other anticancer therapies in preclinical models. ▪️ VS-7375 shows improved KRAS G12D selectivity and potency vs other KRAS G12D

The ultimate ADC review! 40 years of ADC. Must read for residents. 10.1158/2159-8290.CD-24-0708 Dr Akhil Santhosh Dr Vineet Govinda Gupta Valame MD DNB Dr Amol Akhade Ashish Singh Josh Thomas Georgy Ajoy Oommen John

Nonoperative Management of Mismatch Repair–Deficient Tumors in NEJM Ph 2 study, neoadjuvant dostarlimab (PD-1 inh) achieved 82% cCR and 80% organ preservation in stage I–III dMMR tumors, with 92% 2-year RFS; 44% had Lynch syndrome🧬 OncoAlert nejm.org/doi/full/10.10…

Representation of geriatric oncology in cancer care guidelines in Europe: a scoping review by SIOG in ESMO Open. Older adults underrepresented with significant regional disparities. Need for inclusive research and geriatric expertise to enhance outcomes.esmoopen.com/article/S2059-…

🔥🚨OncoAlert Hot Off The Press. Just published NEJM Results of: ⭐️ #Beamion LUNG-1 phase 1a–1b of: #Zongertinib (#Oral, irreversible, HER2 #TKI) in previously treated #Patients with advanced #HER2-mutant non-small- cell #LungCancer (#NSCLC). 👇🏻 nejm.org/doi/full/10.10…

Online now for the #AACR25 session on Advances in #KRAS Biology in PDAC by session speaker Andrew Aguirre: Response and Resistance to RAS inhibition in Cancer brnw.ch/21wSgTw

Key resistance data in patients with #PancreaticCancer receiving PanKRASi Daraxonrasib. By Andrew Aguirre #AACR25 - Amplification of mutant KRAS allele under selection pressure in 1/3rd pts on progression. - No secondary KRAS alterations - Multiple alterations in RAS pathway

Wonderful #OpenAccess review in Cancer Discovery on bridging clinical studies with mechanistic insights on cancer associated cachexia, to coincide with #AACR25 plenary. From the prolific Cancer Grand Challenges CANCAN team Eileen P. White, PhD Marcus Goncalves Tobias Janowitz Mariam Jamal-Hanjani et al.

Interested in the #AACR25 Minisymposium on the Local and Systemic Tumor Microenvironment? Don't miss the Cancer Discovery commentary by Suling Liu, Yuan Wang, Jiawen Feng, Zhihua Liu, and Shengtao Zhou: Building an Organ-Wide Macroscopic View of Cancer Hallmarks doi.org/10.1158/2159-8…

Predictive value of EBV-positivity in patients with gastric cancer treated with first-line nivolumab plus chemotherapy | Gastric Cancer ➡️Small sample size but may be informative ➡️EBV positive and CPS >5 , Nivo plus chemo✅ link.springer.com/article/10.100…